Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
disrupting HIF-2 DNA binding and inhibiting the transcription of its target genes
54(17):6139-50
J Pediatr Hematol Oncol
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist
MLN-9708 - CAS# 1239908-20-3 60262 Allosteric inhibition enhances the efficacyMLN 9708, also known as ixazomib citrate, CAS No. 1239908 20 3, is a prodrug of Ixazomib (MMLN 2238). MLN 9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN 9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN 9708, compared with bortezomib, has improved
US$ 141.00
US$ 70.00
US$ 170.00
US$ 30.00
US$ 19.95
US$ 59.95